Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CDTX 
Cidara Therapeutics Inc (CDTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CDTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $79.8
1 Year Target Price $79.8
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.55% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.65B USD | Price to earnings Ratio - | 1Y Target Price 79.8 |
Price to earnings Ratio - | 1Y Target Price 79.8 | ||
Volume (30-day avg) 5 | Beta 1.19 | 52 Weeks Range 10.14 - 69.36 | Updated Date 08/29/2025 |
52 Weeks Range 10.14 - 69.36 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.63 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-07 | When - | Estimate -3.04 | Actual -1.65 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.61% | Return on Equity (TTM) -37.05% |
Valuation
Trailing PE - | Forward PE 5.75 | Enterprise Value 1145863666 | Price to Sales(TTM) 4540.7 |
Enterprise Value 1145863666 | Price to Sales(TTM) 4540.7 | ||
Enterprise Value to Revenue 0.61 | Enterprise Value to EBITDA -1.64 | Shares Outstanding 25358100 | Shares Floating 16584673 |
Shares Outstanding 25358100 | Shares Floating 16584673 | ||
Percent Insiders 0.89 | Percent Institutions 106.96 |
Upturn AI SWOT
Cidara Therapeutics Inc
Company Overview
History and Background
Cidara Therapeutics Inc. was founded in 2012. It is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives.
Core Business Areas
- Rezafungin Development: Focuses on the development of rezafungin for the treatment and prevention of serious fungal infections.
- Cloudbreak Platform: Development of novel immunotherapy for oncology.
Leadership and Structure
Jeffrey Stein is the President and CEO. The company has a typical biotech organizational structure with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- Rezafungin: A novel echinocandin antifungal being developed for the treatment and prevention of serious invasive fungal infections. Market share data is currently unavailable as the product is still in development. Competitors in the antifungal space include Pfizer (Diflucan), Merck (Cancidas), and Astellas (Mycamine).
Market Dynamics
Industry Overview
The anti-infectives market is driven by the increasing prevalence of drug-resistant infections. There is a high unmet need for new therapies to combat these infections.
Positioning
Cidara Therapeutics is positioned as a company developing novel therapies to address unmet needs in the anti-infectives market. Its competitive advantage lies in the novel mechanism of action of its lead product candidate, rezafungin.
Total Addressable Market (TAM)
The TAM for antifungals is estimated to be several billion USD. Cidara's position depends on successful rezafungin launch, potentially capturing a significant share of this market given its profile if approved.
Upturn SWOT Analysis
Strengths
- Novel antifungal agent (rezafungin)
- Experienced management team
- Strong intellectual property position
Weaknesses
- Reliance on single lead product candidate
- Limited financial resources
- Clinical trial risks
Opportunities
- Potential for FDA approval of rezafungin
- Expansion into new therapeutic areas
- Strategic partnerships
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Generic entry of existing antifungals
Competitors and Market Share
Key Competitors
- PFE
- MRK
- AMGN
Competitive Landscape
Cidara faced intense competition from established pharmaceutical giants. Its advantage was a novel mechanism of action, but it lacked the financial resources and market reach of its competitors.
Major Acquisitions
Melinta Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 124
- Strategic Rationale: Melinta acquired Cidara in 2023. This acquisition brought rezafungin into Melinta's portfolio, strengthening Melinta's position in the anti-infectives market.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth depended on clinical trial advancements and securing partnerships.
Future Projections: Future projections depend on the success of rezafungin and the Cloudbreak platform. Analyst estimates are unavailable post-acquisition.
Recent Initiatives: Recent initiatives included completing clinical trials for rezafungin and seeking regulatory approval.
Summary
Cidara Therapeutics was a clinical-stage biotech company focused on anti-infectives. Its lead product, rezafungin, held promise, but the company faced significant financial constraints and competition. The acquisition by Melinta Therapeutics provides a path for rezafungin's potential commercialization, addressing key challenges Cidara faced as a standalone entity.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Analyst reports (pre-acquisition)
- Industry news sources
Disclaimers:
This analysis is based on publicly available information and analyst estimates and is not financial advice. Market share data is approximate. Information is current as of the date of the acquisition; future performance will depend on Melinta's management of the acquired assets.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cidara Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-04-15 | President, CEO & Executive Director Dr. Jeffrey L. Stein Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.cidara.com |
Full time employees 38 | Website https://www.cidara.com | ||
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.